HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL
The National Medical Products Administration (NMPA) officially approved the New Drug Application (NDA) for lenecabtagene...
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that...
Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials
Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) announced that it has received...
Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...
LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics
LTZ Therapeutics and Eli Lilly (NYSE: LLY) announced a significant strategic collaboration on July 29,...
Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...
China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment
China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...
MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced its Q2 2025 financial results,...
Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered
Shares of Denmark-based biopharma giant Novo Nordisk A/S (NYSE: NVO) dipped over 20% during trading...
YolTech’s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment
China-based YolTech Therapeutics announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products...
Cedicine Biotech’s Umbilical Cord Blood Mononuclear Cell Injection Gains CDE Approval for Clinical Trial
China-based Cedicine Biotechnology announced today that the Center for Drug Evaluation (CDE) of the National...
Alphamab Oncology’s JSKN003 Granted FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer
China-based Alphamab Oncology (HKG: 9966) announced today that its drug candidate JSKN003 has received Orphan...
Pierre Fabre’s Braftovi Approved in China for BRAF V600E-mutant Metastatic Colorectal Cancer
France-based Pierre Fabre Laboratories announced that Braftovi (encorafenib) in combination with cetuximab has been approved...
Henlius Biotech’s HLX14 Recommended for EU Approval by EMA’s CHMP
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) announced on July 28, 2025, that the European...
Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer’s Treatment
China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered...
Boehringer Ingelheim and Re-Vana Partner to Develop First-in-Class Ocular Therapies
German pharmaceutical giant Boehringer Ingelheim (BI) today announced a strategic collaboration and licensing agreement with...
Tigermed Acquires Japan’s Micron CRO to Expand Imaging Expertise in Asia-Pacific
China-based Tigermed (SHE: 300347, HKG: 3347) announced on July 29, 2025, that it has completed...
Eli Lilly’s Mounjaro Approved by China’s NMPA for Type 2 Diabetes Treatment with Insulin
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced that the National Medical Products Administration...
Antengene’s XPOVIO Approved for New Multiple Myeloma Indication by China’s NMPA
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that the China National Medical Products Administration...
Shanghai Biomedicine M&A Fund Acquires Stake in MicroPort via Share Transfer Agreement
The Shanghai Biomedicine Merger and Acquisition Fund under SIIC Capital has entered into a share...